Fig. 4From: Analysis of the relation between adverse events and overall survival in patients treated with pembrolizumab as a first-line treatment for metastatic NSCLCOS in patients treated with antibiotics (36.7%) during pembrolizumab therapy (p =0.2)Back to article page